Organogenesis Financial Statements From 2010 to 2026

ORGO Stock

USD 3.00 0.00 0.00%

Organogenesis Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Organogenesis Holdings' valuation are provided below:

Gross Profit

426.6 M

Profit Margin

0.0656

Market Capitalization

407.4 M

Enterprise Value Revenue

1.105

Revenue

564.2 M

We have found one hundred twenty available trending fundamental ratios for Organogenesis Holdings, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Organogenesis Holdings' recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 2nd of March 2026, Market Cap is likely to grow to about 701.8 M. Also, Enterprise Value is likely to grow to about 707.6 M

Organogenesis Holdings Total Revenue

301.62 Million

Check Organogenesis Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organogenesis Holdings' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 2.2 M or Selling General Administrative of 351 M, as well as many indicators such as Price To Sales Ratio of 1.97, Dividend Yield of 0.0182 or PTB Ratio of 1.44. Organogenesis financial statements analysis is a perfect complement when working with Organogenesis Holdings Valuation or Volatility modules.

Build AI portfolio with Organogenesis Stock

Check out the analysis of Organogenesis Holdings Correlation against competitors.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Organogenesis Holdings Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

343.9 M

598.7 M

241 M

Slightly volatile

Total Current Liabilities

56.5 M

100.1 M

39.7 M

Slightly volatile

Other Liabilities

1.2 M

1.3 M

3.8 M

Very volatile

Accounts Payable

25.5 M

31.9 M

20 M

Slightly volatile

Cash

65.8 M

93.7 M

46.1 M

Slightly volatile

Other Assets

1.09

1.15

4.2 M

Pretty Stable

Long Term Debt

65.7 M

69.9 M

64.8 M

Pretty Stable

Net Receivables

228.3 M

217.5 M

63.7 M

Slightly volatile

Short Term Investments

146.2 K

173.7 K

149.9 K

Slightly volatile

Inventory

22.6 M

29.6 M

18.6 M

Slightly volatile

Other Current Assets

22.5 M

21.4 M

5.5 M

Slightly volatile

Total Liabilities

119.7 M

164.8 M

83.9 M

Slightly volatile

Total Current Assets

380.3 M

362.2 M

122.2 M

Slightly volatile

Common Stock

11.1 K

11.7 K

34.6 M

Pretty Stable

Property Plant Equipment

123.7 M

117.8 M

64.2 M

Slightly volatile

Short and Long Term Debt Total

84 M

82.1 M

51 M

Slightly volatile

Non Current Assets Total

205.3 M

236.5 M

132.9 M

Slightly volatile

Cash And Short Term Investments

71.7 M

93.7 M

46.4 M

Slightly volatile

Common Stock Shares Outstanding

107 M

130.2 M

87.7 M

Slightly volatile

Liabilities And Stockholders Equity

361.5 M

464.9 M

234 M

Slightly volatile

Non Current Liabilities Total

68.6 M

64.7 M

44.4 M

Slightly volatile

Capital Surpluse

182.7 M

357.6 M

146.5 M

Slightly volatile

Non Current Liabilities Other

764.4 K

804.6 K

145.5 M

Slightly volatile

Net Invested Capital

275.1 M

302.3 M

274.4 M

Very volatile

Property Plant And Equipment Net

118.1 M

159.5 M

76.1 M

Slightly volatile

Current Deferred Revenue

30.6 M

41.1 M

31.4 M

Slightly volatile

Long Term Debt Total

76.6 M

76.2 M

60.4 M

Slightly volatile

Capital Lease Obligations

40.6 M

49.8 M

28.8 M

Slightly volatile

Property Plant And Equipment Gross

133.5 M

229.1 M

89.9 M

Slightly volatile

Capital Stock

147.8 M

140.8 M

24.2 M

Slightly volatile

Organogenesis Holdings Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Selling General Administrative

351 M

334.3 M

137.1 M

Slightly volatile

Research Development

25.3 M

44.5 M

18.6 M

Slightly volatile

Cost Of Revenue

72.6 M

133.1 M

65.7 M

Slightly volatile

Total Operating Expenses

545.4 M

519.5 M

223.2 M

Slightly volatile

Interest Income

10.9 M

10.3 M

5.6 M

Slightly volatile

Reconciled Depreciation

15.2 M

19.6 M

11 M

Slightly volatile

Selling And Marketing Expenses

4.2 M

4.4 M

2.4 M

Slightly volatile

Organogenesis Holdings Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation

12.1 M

18.6 M

10.3 M

Slightly volatile

Capital Expenditures

13.3 M

14.2 M

9.4 M

Slightly volatile

End Period Cash Flow

66.2 M

94.3 M

46.7 M

Slightly volatile

Stock Based Compensation

14 M

13.3 M

3.8 M

Slightly volatile

Begin Period Cash Flow

143 M

136.2 M

45.7 M

Slightly volatile

Cash Flows Other Operating

14.6 M

19.6 M

8.3 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.97

1.1637

2.661

Slightly volatile

Dividend Yield

0.0182

0.0173

0.0059

Slightly volatile

PTB Ratio

1.44

1.513

2.6422

Pretty Stable

Days Sales Outstanding

148

141

74.8531

Slightly volatile

Book Value Per Share

6.01

3.4237

15.913

Slightly volatile

Stock Based Compensation To Revenue

0.0247

0.0236

0.0101

Slightly volatile

Capex To Depreciation

0.82

0.761

0.7261

Slightly volatile

PB Ratio

1.44

1.513

2.6422

Pretty Stable

EV To Sales

2.0

1.1432

2.7706

Slightly volatile

Inventory Turnover

3.36

5.0328

4.6071

Slightly volatile

Days Of Inventory On Hand

98.34

72.5241

81.1067

Slightly volatile

Payables Turnover

2.62

4.667

1.9897

Slightly volatile

Sales General And Administrative To Revenue

0.67

0.69

0.6246

Slightly volatile

Research And Ddevelopement To Revenue

0.0611

0.079

0.0657

Slightly volatile

Capex To Revenue

0.033

0.0251

0.0259

Slightly volatile

Cash Per Share

0.49

0.7392

0.4306

Slightly volatile

Payout Ratio

0.19

0.1998

1.8655

Slightly volatile

Days Payables Outstanding

74.3

78.2082

765

Slightly volatile

Intangibles To Total Assets

0.0602

0.0633

0.2229

Slightly volatile

Current Ratio

1.82

3.6174

1.6619

Slightly volatile

Receivables Turnover

2.46

2.5945

5.2418

Slightly volatile

Graham Number

6.18

5.8813

2.701

Slightly volatile

Shareholders Equity Per Share

6.01

3.4237

15.913

Slightly volatile

Capex Per Share

0.1

0.1117

0.1402

Very volatile

Revenue Per Share

2.73

4.4515

3.0851

Slightly volatile

Interest Debt Per Share

0.89

0.6661

0.7625

Slightly volatile

Debt To Assets

0.13

0.1372

0.2902

Slightly volatile

Operating Cycle

133

213

149

Slightly volatile

Price Book Value Ratio

1.44

1.513

2.6422

Pretty Stable

Days Of Payables Outstanding

74.3

78.2082

765

Slightly volatile

Dividend Payout Ratio

0.19

0.1998

1.8655

Slightly volatile

Ebt Per Ebit

0.85

1.0509

0.7978

Slightly volatile

Long Term Debt To Capitalization

0.14

0.15

0.3516

Slightly volatile

Total Debt To Capitalization

0.15

0.1592

0.5339

Slightly volatile

Quick Ratio

3.49

3.3215

1.6067

Slightly volatile

Cash Ratio

0.86

0.9356

0.8335

Slightly volatile

Days Of Inventory Outstanding

98.34

72.5241

81.1067

Slightly volatile

Days Of Sales Outstanding

148

141

74.8531

Slightly volatile

Price To Book Ratio

1.44

1.513

2.6422

Pretty Stable

Fixed Asset Turnover

4.59

3.538

4.5288

Slightly volatile

Debt Ratio

0.13

0.1372

0.2902

Slightly volatile

Price Sales Ratio

1.97

1.1637

2.661

Slightly volatile

Asset Turnover

1.16

0.9423

1.1209

Slightly volatile

Gross Profit Margin

0.58

0.7357

0.6825

Slightly volatile

Price Fair Value

1.44

1.513

2.6422

Pretty Stable

Organogenesis Holdings Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

701.8 M

656.5 M

640 M

Very volatile

Enterprise Value

707.6 M

645 M

650.4 M

Very volatile

Organogenesis Fundamental Market Drivers

	Forward Price Earnings	12.3153
	Cash And Short Term Investments	93.7 M

Organogenesis Upcoming Events

	6th of March 2024 Upcoming Quarterly Report	View
	8th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	6th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Organogenesis Holdings Financial Statements

Organogenesis Holdings investors utilize fundamental indicators, such as revenue or net income, to predict how Organogenesis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	41.1 M	30.6 M
Total Revenue	564.2 M	301.6 M
Cost Of Revenue	133.1 M	72.6 M
Stock Based Compensation To Revenue	0.02	0.02
Sales General And Administrative To Revenue	0.69	0.67
Research And Ddevelopement To Revenue	0.08	0.06
Capex To Revenue	0.03	0.03
Revenue Per Share	4.45	2.73
Ebit Per Revenue	0.08	0.08

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Organogenesis Stock

0.73

OSE

OSE Pharma SA

Pair Corr

Moving against Organogenesis Stock

0.8	8VP1	AVRICORE HEALTH INC	Pair Corr
0.76	GXEA	Galapagos NV	Pair Corr
0.76	VALN	Valneva SE ADR	Pair Corr
0.61	DNTH	Dianthus Therapeutics	Pair Corr
0.58	DNLI	Denali Therapeutics	Pair Corr

The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.

The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:

How To Invest In Organogenesis

Details

Is Organogenesis Stock a good investment?

Details

What is Organogenesis Holdings' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Organogenesis Holdings Correlation against competitors.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

5.145

Earnings Share

(0.08)

Revenue Per Share

4.451

Quarterly Revenue Growth

0.781

Return On Assets

0.0643

Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.

It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Organogenesis Financial Statements From 2010 to 2026

Organogenesis Holdings Total Revenue

301.62 Million

Organogenesis Holdings Balance Sheet

Organogenesis Holdings Income Statement

Organogenesis Holdings Cash Flow Statement

Financial Ratios

Organogenesis Holdings Valuation Data

Organogenesis Fundamental Market Drivers

Organogenesis Upcoming Events

About Organogenesis Holdings Financial Statements

Pair Trading with Organogenesis Holdings

Moving together with Organogenesis Stock

Moving against Organogenesis Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY